Condition: Prostate Cancer · Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy
This description comes directly from the study's public registry record.
Daria Handkiewicz-Junak · 48322789339 · daria.handkiewicz-junak@gliwice.nio.gov.pl
Agnieszka Ciomber · 48322789797 · agnieszka.ciomber@gliwice.nio.gov.pl
Always discuss trial participation with your own doctor first.
| Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch | Gliwice, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06449781